 | • レポートコード：MRC2-11QY12585 • 出版社/出版日：QYResearch / 2020年11月25日 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、98ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：ヘルスケア |
| Single User | ￥585,000 (USD3,900) | ▷ お問い合わせ |
| Multi User | ￥877,500 (USD5,850) | ▷ お問い合わせ |
| Enterprise License | ￥1,170,000 (USD7,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 当調査資料は悪性中皮腫治療のグローバル市場について調査・分析したレポートです。種類別（ペメトレキセド、シスプラチン、その他）市場規模、用途別（胸膜中皮腫、腹膜中皮腫、その他）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国、韓国、インド、オーストラリア、台湾、中南米、メキシコ、ブラジル、アルゼンチン、中東・アフリカ、トルコ、サウジアラビア、UAE等）市場規模データ、主な企業情報と企業別市場シェア等が収録されています。 ・調査範囲 ・エグゼクティブサマリー ・企業別悪性中皮腫治療の競争状況、市場シェア ・世界の悪性中皮腫治療市場：種類別市場規模 2015年-2020年（ペメトレキセド、シスプラチン、その他） ・世界の悪性中皮腫治療市場：種類別市場規模予測 2021年-2026年（ペメトレキセド、シスプラチン、その他） ・世界の悪性中皮腫治療市場：用途別市場規模 2015年-2020年（胸膜中皮腫、腹膜中皮腫、その他） ・世界の悪性中皮腫治療市場：用途別市場規模予測 2021年-2026年（胸膜中皮腫、腹膜中皮腫、その他） ・北米の悪性中皮腫治療市場分析：米国、カナダ ・ヨーロッパの悪性中皮腫治療市場分析：ドイツ、フランス、イギリス、イタリア、ロシア等 ・アジアの悪性中皮腫治療市場分析：日本、中国、韓国、インド、オーストラリア、台湾等 ・中南米の悪性中皮腫治療市場分析：メキシコ、ブラジル、アルゼンチン等 ・中東・アフリカの悪性中皮腫治療市場分析：トルコ、サウジアラビア、UAE等 ・企業情報（企業概要、製品概要、販売量、企業動向） - 掲載企業（変更可能性あり）：Eli Lilly、Teva、Sanofi、Bristol-Myers Squibb、Pfizer、Roche、Merck、Ono Pharmaceutical、Mylan、Fresenius Kabi、Sun Pharmaceuticals ・地域別市場規模予測（2021年-2026年）：北米市場、ヨーロッパ市場、アジア市場、中南米市場、中東・アフリカ市場 ・市場機会、課題、リスク、環境分析 ・バリューチェーン、販売チャネル分析 ・調査の結論 |
Mesothelioma is a type of cancer that develops from the thin layer of tissue that covers many of the internal organs (known as the mesothelium).
Malignant mesothelioma is a cancer of the thin tissue (mesothelium) that lines the lung, chest wall, and abdomen. The major risk factor for mesothelioma is asbestos exposure.
The classification of Malignant Mesothelioma Therapeutic includes Pemetrexed, Cisplatin and others. The proportion of Pemetrexed in 2019 approaches 50%. Malignant Mesothelioma Therapeutic is mostly used for Pleural Mesothelioma, and the proportion in 2019 is about 80%. Europe is the largest market, with a sales market share above 50% in 2019. Following Europe, Asia Pacific is the second largest sales place with the sales market share of above 1/5. Market competition is intense. Eli Lilly, Teva, Sanofi, Bristol-Myers Squibb, etc. are the leaders of the industry, and they hold key technologies and patents, with high-end customers.
Market Analysis and Insights: Global Malignant Mesothelioma Therapeutic Market
The global Malignant Mesothelioma Therapeutic market size is projected to reach US$ 462.6 million by 2026, from US$ 308.8 million in 2020, at a CAGR of 7.0% during 2021-2026.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Malignant Mesothelioma Therapeutic market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Malignant Mesothelioma Therapeutic market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Malignant Mesothelioma Therapeutic market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Malignant Mesothelioma Therapeutic market.
Global Malignant Mesothelioma Therapeutic Scope and Market Size
Malignant Mesothelioma Therapeutic market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Malignant Mesothelioma Therapeutic market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2015-2026.
Market segment by Type, the product can be split into
Pemetrexed
Cisplatin
Others
Market segment by Application, split into
Pleural Mesothelioma
Peritoneal Mesothelioma
Others
Based on regional and country-level analysis, the Malignant Mesothelioma Therapeutic market has been segmented as follows:
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia-Pacific
Latin America
Mexico
Brazil
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of Middle East & Africa
In the competitive analysis section of the report, leading as well as prominent players of the global Malignant Mesothelioma Therapeutic market are broadly studied on the basis of key factors. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on price and revenue (global level) by player for the period 2015-2020.
The key players covered in this study
Eli Lilly
Teva
Sanofi
Bristol-Myers Squibb
Pfizer
Roche
Merck
Ono Pharmaceutical
Mylan
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Malignant Mesothelioma Therapeutic Market Size Growth Rate by Type: 2020 VS 2026
1.2.2 Pemetrexed
1.2.3 Cisplatin
1.2.4 Others
1.3 Market by Application
1.3.1 Global Malignant Mesothelioma Therapeutic Market Share by Application: 2020 VS 2026
1.3.2 Pleural Mesothelioma
1.3.3 Peritoneal Mesothelioma
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Malignant Mesothelioma Therapeutic Market Perspective (2015-2026)
2.2 Global Malignant Mesothelioma Therapeutic Growth Trends by Regions
2.2.1 Malignant Mesothelioma Therapeutic Market Size by Regions: 2015 VS 2020 VS 2026
2.2.2 Malignant Mesothelioma Therapeutic Historic Market Share by Regions (2015-2020)
2.2.3 Malignant Mesothelioma Therapeutic Forecasted Market Size by Regions (2021-2026)
2.3 Industry Trends and Growth Strategy
2.3.1 Market Trends
2.3.2 Market Drivers
2.3.3 Market Challenges
2.3.4 Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Malignant Mesothelioma Therapeutic Players by Market Size
3.1.1 Global Top Malignant Mesothelioma Therapeutic Players by Revenue (2015-2020)
3.1.2 Global Malignant Mesothelioma Therapeutic Revenue Market Share by Players (2015-2020)
3.2 Global Malignant Mesothelioma Therapeutic Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Malignant Mesothelioma Therapeutic Revenue
3.4 Global Malignant Mesothelioma Therapeutic Market Concentration Ratio
3.4.1 Global Malignant Mesothelioma Therapeutic Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Malignant Mesothelioma Therapeutic Revenue in 2019
3.5 Key Players Malignant Mesothelioma Therapeutic Area Served
3.6 Key Players Malignant Mesothelioma Therapeutic Product Solution and Service
3.7 Date of Enter into Malignant Mesothelioma Therapeutic Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Malignant Mesothelioma Therapeutic Breakdown Data by Type (2015-2026)
4.1 Global Malignant Mesothelioma Therapeutic Historic Market Size by Type (2015-2020)
4.2 Global Malignant Mesothelioma Therapeutic Forecasted Market Size by Type (2021-2026)
5 Malignant Mesothelioma Therapeutic Breakdown Data by Application (2015-2026)
5.1 Global Malignant Mesothelioma Therapeutic Historic Market Size by Application (2015-2020)
5.2 Global Malignant Mesothelioma Therapeutic Forecasted Market Size by Application (2021-2026)
6 North America
6.1 North America Malignant Mesothelioma Therapeutic Market Size (2015-2026)
6.2 North America Malignant Mesothelioma Therapeutic Market Size by Type (2015-2020)
6.3 North America Malignant Mesothelioma Therapeutic Market Size by Application (2015-2020)
6.4 North America Malignant Mesothelioma Therapeutic Market Size by Country (2015-2020)
6.4.1 United States
6.4.2 Canada
7 Europe
7.1 Europe Malignant Mesothelioma Therapeutic Market Size (2015-2026)
7.2 Europe Malignant Mesothelioma Therapeutic Market Size by Type (2015-2020)
7.3 Europe Malignant Mesothelioma Therapeutic Market Size by Application (2015-2020)
7.4 Europe Malignant Mesothelioma Therapeutic Market Size by Country (2015-2020)
7.4.1 Germany
7.4.2 France
7.4.3 U.K.
7.4.4 Italy
7.4.5 Russia
7.4.6 Nordic
7.4.7 Rest of Europe
8 India
8.1 India Malignant Mesothelioma Therapeutic Market Size (2015-2026)
8.2 India Malignant Mesothelioma Therapeutic Market Size by Type (2015-2020)
8.3 India Malignant Mesothelioma Therapeutic Market Size by Application (2015-2020)
8.4 India Malignant Mesothelioma Therapeutic Market Size by Region (2015-2020)
8.4.1 China
8.4.2 Japan
8.4.3 South Korea
8.4.4 Southeast Asia
8.4.5 India
8.4.6 Australia
8.4.7 Rest of Asia-Pacific
9 Japan
9.1 Japan Malignant Mesothelioma Therapeutic Market Size (2015-2026)
9.2 Japan Malignant Mesothelioma Therapeutic Market Size by Type (2015-2020)
9.3 Japan Malignant Mesothelioma Therapeutic Market Size by Application (2015-2020)
9.4 Japan Malignant Mesothelioma Therapeutic Market Size by Country (2015-2020)
9.4.1 Mexico
9.4.2 Brazil
10 China
10.1 China Malignant Mesothelioma Therapeutic Market Size (2015-2026)
10.2 China Malignant Mesothelioma Therapeutic Market Size by Type (2015-2020)
10.3 China Malignant Mesothelioma Therapeutic Market Size by Application (2015-2020)
10.4 China Malignant Mesothelioma Therapeutic Market Size by Country (2015-2020)
10.4.1 Turkey
10.4.2 Saudi Arabia
10.4.3 UAE
10.4.4 Rest of Middle East & Africa
11Key Players Profiles
11.1 Eli Lilly
11.1.1 Eli Lilly Company Details
11.1.2 Eli Lilly Business Overview
11.1.3 Eli Lilly Malignant Mesothelioma Therapeutic Introduction
11.1.4 Eli Lilly Revenue in Malignant Mesothelioma Therapeutic Business (2015-2020))
11.1.5 Eli Lilly Recent Development
11.2 Teva
11.2.1 Teva Company Details
11.2.2 Teva Business Overview
11.2.3 Teva Malignant Mesothelioma Therapeutic Introduction
11.2.4 Teva Revenue in Malignant Mesothelioma Therapeutic Business (2015-2020)
11.2.5 Teva Recent Development
11.3 Sanofi
11.3.1 Sanofi Company Details
11.3.2 Sanofi Business Overview
11.3.3 Sanofi Malignant Mesothelioma Therapeutic Introduction
11.3.4 Sanofi Revenue in Malignant Mesothelioma Therapeutic Business (2015-2020)
11.3.5 Sanofi Recent Development
11.4 Bristol-Myers Squibb
11.4.1 Bristol-Myers Squibb Company Details
11.4.2 Bristol-Myers Squibb Business Overview
11.4.3 Bristol-Myers Squibb Malignant Mesothelioma Therapeutic Introduction
11.4.4 Bristol-Myers Squibb Revenue in Malignant Mesothelioma Therapeutic Business (2015-2020)
11.4.5 Bristol-Myers Squibb Recent Development
11.5 Pfizer
11.5.1 Pfizer Company Details
11.5.2 Pfizer Business Overview
11.5.3 Pfizer Malignant Mesothelioma Therapeutic Introduction
11.5.4 Pfizer Revenue in Malignant Mesothelioma Therapeutic Business (2015-2020)
11.5.5 Pfizer Recent Development
11.6 Roche
11.6.1 Roche Company Details
11.6.2 Roche Business Overview
11.6.3 Roche Malignant Mesothelioma Therapeutic Introduction
11.6.4 Roche Revenue in Malignant Mesothelioma Therapeutic Business (2015-2020)
11.6.5 Roche Recent Development
11.7 Merck
11.7.1 Merck Company Details
11.7.2 Merck Business Overview
11.7.3 Merck Malignant Mesothelioma Therapeutic Introduction
11.7.4 Merck Revenue in Malignant Mesothelioma Therapeutic Business (2015-2020)
11.7.5 Merck Recent Development
11.8 Ono Pharmaceutical
11.8.1 Ono Pharmaceutical Company Details
11.8.2 Ono Pharmaceutical Business Overview
11.8.3 Ono Pharmaceutical Malignant Mesothelioma Therapeutic Introduction
11.8.4 Ono Pharmaceutical Revenue in Malignant Mesothelioma Therapeutic Business (2015-2020)
11.8.5 Ono Pharmaceutical Recent Development
11.9 Mylan
11.9.1 Mylan Company Details
11.9.2 Mylan Business Overview
11.9.3 Mylan Malignant Mesothelioma Therapeutic Introduction
11.9.4 Mylan Revenue in Malignant Mesothelioma Therapeutic Business (2015-2020)
11.9.5 Mylan Recent Development
11.10 Fresenius Kabi
11.10.1 Fresenius Kabi Company Details
11.10.2 Fresenius Kabi Business Overview
11.10.3 Fresenius Kabi Malignant Mesothelioma Therapeutic Introduction
11.10.4 Fresenius Kabi Revenue in Malignant Mesothelioma Therapeutic Business (2015-2020)
11.10.5 Fresenius Kabi Recent Development
11.11 Sun Pharmaceuticals
10.11.1 Sun Pharmaceuticals Company Details
10.11.2 Sun Pharmaceuticals Business Overview
10.11.3 Sun Pharmaceuticals Malignant Mesothelioma Therapeutic Introduction
10.11.4 Sun Pharmaceuticals Revenue in Malignant Mesothelioma Therapeutic Business (2015-2020)
10.11.5 Sun Pharmaceuticals Recent Development
12Analyst’s Viewpoints/Conclusions
13Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Table 1. Global Malignant Mesothelioma Therapeutic Market Size Growth Rate by Type (US$ Million): 2020 VS 2026
Table 3. Key Players of Pemetrexed
Table 4. Key Players of Cisplatin
Table 5. Key Players of Others
Table 6. Global Malignant Mesothelioma Therapeutic Market Size Growth by Application (US$ Million): 2020 VS 2026
Table 7. Global Malignant Mesothelioma Therapeutic Market Size by Regions (US$ Million): 2020 VS 2026
Table 8. Global Malignant Mesothelioma Therapeutic Market Size by Regions (2015-2020) (US$ Million)
Table 9. Global Malignant Mesothelioma Therapeutic Market Share by Regions (2015-2020)
Table 10. Global Malignant Mesothelioma Therapeutic Forecasted Market Size by Regions (2021-2026) (US$ Million)
Table 11. Global Malignant Mesothelioma Therapeutic Market Share by Regions (2021-2026)
Table 12. Malignant Mesothelioma Therapeutic Market Market Trends
Table 13. Malignant Mesothelioma Therapeutic Market Drivers
Table 14. Malignant Mesothelioma Therapeutic Market Challenges
Table 15. Malignant Mesothelioma Therapeutic Market Restraints
Table 16. Global Malignant Mesothelioma Therapeutic Revenue by Players (2015-2020) (US$ Million)
Table 17. Global Malignant Mesothelioma Therapeutic Market Share by Players (2015-2020)
Table 18. Global Top Malignant Mesothelioma Therapeutic Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Malignant Mesothelioma Therapeutic as of 2019)
Table 19. Global Malignant Mesothelioma Therapeutic by Players Market Concentration Ratio (CR5 and HHI)
Table 20. Key Players Headquarters and Area Served
Table 21. Key Players Malignant Mesothelioma Therapeutic Product Solution and Service
Table 22. Mergers & Acquisitions, Expansion Plans
Table 23. Global Malignant Mesothelioma Therapeutic Market Size by Type (2015-2020) (US$ Million)
Table 24. Global Malignant Mesothelioma Therapeutic Market Size Share by Type (2015-2020)
Table 25. Global Malignant Mesothelioma Therapeutic Revenue Market Share by Type (2021-2026)
Table 26. Global Malignant Mesothelioma Therapeutic Market Size Share by Application (2015-2020)
Table 27. Global Malignant Mesothelioma Therapeutic Market Size by Application (2015-2020) (US$ Million)
Table 28. Global Malignant Mesothelioma Therapeutic Market Size Share by Application (2021-2026)
Table 29. North America Malignant Mesothelioma Therapeutic Market Size by Type (2015-2020) (US$ Million)
Table 30. North America Malignant Mesothelioma Therapeutic Market Share by Type (2015-2020)
Table 31. North America Malignant Mesothelioma Therapeutic Market Size by Application (2015-2020) (US$ Million)
Table 32. North America Malignant Mesothelioma Therapeutic Market Share by Application (2015-2020)
Table 33. North America Malignant Mesothelioma Therapeutic Market Size by Country (US$ Million) (2015-2020)
Table 34. North America Malignant Mesothelioma Therapeutic Market Share by Country (2015-2020)
Table 35. Europe Malignant Mesothelioma Therapeutic Market Size by Type (2015-2020) (US$ Million)
Table 36. Europe Malignant Mesothelioma Therapeutic Market Share by Type (2015-2020)
Table 37. Europe Malignant Mesothelioma Therapeutic Market Size by Application (2015-2020) (US$ Million)
Table 38. Europe Malignant Mesothelioma Therapeutic Market Share by Application (2015-2020)
Table 39. Europe Malignant Mesothelioma Therapeutic Market Size by Country (US$ Million) (2015-2020)
Table 40. Europe Malignant Mesothelioma Therapeutic Market Share by Country (2015-2020)
Table 41. India Malignant Mesothelioma Therapeutic Market Size by Type (2015-2020) (US$ Million)
Table 42. India Malignant Mesothelioma Therapeutic Market Share by Type (2015-2020)
Table 43. India Malignant Mesothelioma Therapeutic Market Size by Application (2015-2020) (US$ Million)
Table 44. India Malignant Mesothelioma Therapeutic Market Share by Application (2015-2020)
Table 45. India Malignant Mesothelioma Therapeutic Market Size by Region (US$ Million) (2015-2020)
Table 46. India Malignant Mesothelioma Therapeutic Market Share by Region (2015-2020)
Table 47. Japan Malignant Mesothelioma Therapeutic Market Size by Type (2015-2020) (US$ Million)
Table 48. Japan Malignant Mesothelioma Therapeutic Market Share by Type (2015-2020)
Table 49. Japan Malignant Mesothelioma Therapeutic Market Size by Application (2015-2020) (US$ Million)
Table 50. Japan Malignant Mesothelioma Therapeutic Market Share by Application (2015-2020)
Table 51. Japan Malignant Mesothelioma Therapeutic Market Size by Country (US$ Million) (2015-2020)
Table 52. Japan Malignant Mesothelioma Therapeutic Market Share by Country (2015-2020)
Table 53. China Malignant Mesothelioma Therapeutic Market Size by Type (2015-2020) (US$ Million)
Table 54. China Malignant Mesothelioma Therapeutic Market Share by Type (2015-2020)
Table 55. China Malignant Mesothelioma Therapeutic Market Size by Application (2015-2020) (US$ Million)
Table 56. China Malignant Mesothelioma Therapeutic Market Share by Application (2015-2020)
Table 57. China Malignant Mesothelioma Therapeutic Market Size by Country (US$ Million) (2015-2020)
Table 58. China Malignant Mesothelioma Therapeutic Market Share by Country (2015-2020)
Table 59. Eli Lilly Company Details
Table 60. Eli Lilly Business Overview
Table 61. Eli Lilly Product
Table 62. Eli Lilly Revenue in Malignant Mesothelioma Therapeutic Business (2015-2020) (US$ Million)
Table 63. Eli Lilly Recent Development
Table 64. Teva Company Details
Table 65. Teva Business Overview
Table 66. Teva Product
Table 67. Teva Revenue in Malignant Mesothelioma Therapeutic Business (2015-2020) (US$ Million)
Table 68. Teva Recent Development
Table 69. Sanofi Company Details
Table 70. Sanofi Business Overview
Table 71. Sanofi Product
Table 72. Sanofi Revenue in Malignant Mesothelioma Therapeutic Business (2015-2020) (US$ Million)
Table 73. Sanofi Recent Development
Table 74. Bristol-Myers Squibb Company Details
Table 75. Bristol-Myers Squibb Business Overview
Table 76. Bristol-Myers Squibb Product
Table 77. Bristol-Myers Squibb Revenue in Malignant Mesothelioma Therapeutic Business (2015-2020) (US$ Million)
Table 78. Bristol-Myers Squibb Recent Development
Table 79. Pfizer Company Details
Table 80. Pfizer Business Overview
Table 81. Pfizer Product
Table 82. Pfizer Revenue in Malignant Mesothelioma Therapeutic Business (2015-2020) (US$ Million)
Table 83. Pfizer Recent Development
Table 84. Roche Company Details
Table 85. Roche Business Overview
Table 86. Roche Product
Table 87. Roche Revenue in Malignant Mesothelioma Therapeutic Business (2015-2020) (US$ Million)
Table 88. Roche Recent Development
Table 89. Merck Company Details
Table 90. Merck Business Overview
Table 91. Merck Product
Table 92. Merck Revenue in Malignant Mesothelioma Therapeutic Business (2015-2020) (US$ Million)
Table 93. Merck Recent Development
Table 94. Ono Pharmaceutical Business Overview
Table 95. Ono Pharmaceutical Product
Table 96. Ono Pharmaceutical Company Details
Table 97. Ono Pharmaceutical Revenue in Malignant Mesothelioma Therapeutic Business (2015-2020) (US$ Million)
Table 98. Ono Pharmaceutical Recent Development
Table 99. Mylan Company Details
Table 100. Mylan Business Overview
Table 101. Mylan Product
Table 102. Mylan Revenue in Malignant Mesothelioma Therapeutic Business (2015-2020) (US$ Million)
Table 103. Mylan Recent Development
Table 104. Fresenius Kabi Company Details
Table 105. Fresenius Kabi Business Overview
Table 106. Fresenius Kabi Product
Table 107. Fresenius Kabi Revenue in Malignant Mesothelioma Therapeutic Business (2015-2020) (US$ Million)
Table 108. Fresenius Kabi Recent Development
Table 109. Sun Pharmaceuticals Company Details
Table 110. Sun Pharmaceuticals Business Overview
Table 111. Sun Pharmaceuticals Product
Table 112. Sun Pharmaceuticals Revenue in Malignant Mesothelioma Therapeutic Business (2015-2020) (US$ Million)
Table 113. Sun Pharmaceuticals Recent Development
Table 114. Research Programs/Design for This Report
Table 115. Key Data Information from Secondary Sources
Table 116. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Malignant Mesothelioma Therapeutic Market Share by Type: 2020 VS 2026
Figure 2. Pemetrexed Features
Figure 3. Cisplatin Features
Figure 4. Others Features
Figure 5. Global Malignant Mesothelioma Therapeutic Market Share by Application: 2020 VS 2026
Figure 6. Pleural Mesothelioma Case Studies
Figure 7. Peritoneal Mesothelioma Case Studies
Figure 8. Others Case Studies
Figure 9. Malignant Mesothelioma Therapeutic Report Years Considered
Figure 10. Global Malignant Mesothelioma Therapeutic Market Size (US$ Million), YoY Growth 2015-2026
Figure 11. Global Malignant Mesothelioma Therapeutic Market Share by Regions: 2020 VS 2026
Figure 12. Global Malignant Mesothelioma Therapeutic Market Share by Regions (2021-2026)
Figure 13. Global Malignant Mesothelioma Therapeutic Market Share by Players in 2019
Figure 14. Global Top Malignant Mesothelioma Therapeutic Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Malignant Mesothelioma Therapeutic as of 2019
Figure 15. The Top 10 and 5 Players Market Share by Malignant Mesothelioma Therapeutic Revenue in 2019
Figure 16. North America Malignant Mesothelioma Therapeutic Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 17. United States Malignant Mesothelioma Therapeutic Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 18. Canada Malignant Mesothelioma Therapeutic Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 19. Europe Malignant Mesothelioma Therapeutic Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 20. Germany Malignant Mesothelioma Therapeutic Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 21. France Malignant Mesothelioma Therapeutic Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 22. U.K. Malignant Mesothelioma Therapeutic Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 23. Italy Malignant Mesothelioma Therapeutic Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 24. Russia Malignant Mesothelioma Therapeutic Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 25. Nordic Malignant Mesothelioma Therapeutic Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 26. Rest of Europe Malignant Mesothelioma Therapeutic Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 27. Asia-Pacific Malignant Mesothelioma Therapeutic Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 28. China Malignant Mesothelioma Therapeutic Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 29. Japan Malignant Mesothelioma Therapeutic Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 30. South Korea Malignant Mesothelioma Therapeutic Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 31. Southeast Asia Malignant Mesothelioma Therapeutic Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 32. India Malignant Mesothelioma Therapeutic Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 33. Australia Malignant Mesothelioma Therapeutic Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 34. Rest of Asia-Pacific Malignant Mesothelioma Therapeutic Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 35. Latin America Malignant Mesothelioma Therapeutic Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 36. Mexico Malignant Mesothelioma Therapeutic Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 37. Brazil Malignant Mesothelioma Therapeutic Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 38. Middle East & Africa Malignant Mesothelioma Therapeutic Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 39. Turkey Malignant Mesothelioma Therapeutic Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 40. Saudi Arabia Malignant Mesothelioma Therapeutic Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 41. UAE Malignant Mesothelioma Therapeutic Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 42. Rest of Middle East & Africa Malignant Mesothelioma Therapeutic Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 43. Eli Lilly Revenue Growth Rate in Malignant Mesothelioma Therapeutic Business (2015-2020)
Figure 44. Teva Revenue Growth Rate in Malignant Mesothelioma Therapeutic Business (2015-2020)
Figure 45. Sanofi Revenue Growth Rate in Malignant Mesothelioma Therapeutic Business (2015-2020)
Figure 46. Bristol-Myers Squibb Revenue Growth Rate in Malignant Mesothelioma Therapeutic Business (2015-2020)
Figure 47. Pfizer Revenue Growth Rate in Malignant Mesothelioma Therapeutic Business (2015-2020)
Figure 48. Roche Revenue Growth Rate in Malignant Mesothelioma Therapeutic Business (2015-2020)
Figure 49. Merck Revenue Growth Rate in Malignant Mesothelioma Therapeutic Business (2015-2020)
Figure 50. Ono Pharmaceutical Revenue Growth Rate in Malignant Mesothelioma Therapeutic Business (2015-2020)
Figure 51. Mylan Revenue Growth Rate in Malignant Mesothelioma Therapeutic Business (2015-2020)
Figure 52. Fresenius Kabi Revenue Growth Rate in Malignant Mesothelioma Therapeutic Business (2015-2020)
Figure 53. Sun Pharmaceuticals Revenue Growth Rate in Malignant Mesothelioma Therapeutic Business (2015-2020)
Figure 54. Bottom-up and Top-down Approaches for This Report
Figure 55. Data Triangulation
Figure 56. Key Executives Interviewed
悪性中皮腫治療薬の世界市場（～2026年） Mesothelioma is a type of cancer that develops from the thin layer of tissue that covers many of the internal organs (known as the mesothelium). Our research indicates that the hospital pharmacies distribution channel segment is expected to witness a significant rise in revenue share over the foreca…- 悪性中皮腫の世界市場（～2026年） Mesothelioma is a type of cancer that develops from the thin layer of tissue that covers many of the internal organs (known as the mesothelium). Our research indicates that the hospital pharmacies distribution channel segment is expected to witness a significant rise in revenue share over the foreca…
- 悪性神経膠腫治療の世界市場（～2026年） Malignant glioma's are one of the common sub-type of primary brain tumors which are highly invasive, aggressive and neurologically destructive tumors among the deadliest human cancers. In the Malignant Glioma Market the largest market share is gained by the U.S. where there are large incidence and p…
- 悪性リンパ腫の世界市場（～2026年） Cancers that start anywhere in the body’s lymphatic system are called lymphomas. If they have the ability to spread, they are called malignant. The lymphatic system runs throughout our bodies and is composed of lymphoid tissue, vessels, and fluid. Lymphoid tissue contains lymph nodes, which are part…
- 悪性神経膠腫の世界市場（～2026年） Malignant glioma's are one of the common sub-type of primary brain tumors which are highly invasive, aggressive and neurologically destructive tumors among the deadliest human cancers. In the Malignant Glioma Market the largest market share is gained by the U.S. where there are large incidence and p…